The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2007, 178, 6123 -6129
Copyright © 2007 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, X.
Right arrow Articles by Oppenheim, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, X.
Right arrow Articles by Oppenheim, J. J.

Pertussis Toxin by Inducing IL-6 Promotes the Generation of IL-17-Producing CD4 Cells1

Xin Chen2,*, O. M. Zack Howard{dagger} and Joost J. Oppenheim{dagger}

* Basic Research Program, SAIC-Frederick, National Cancer Institute-Frederick, Frederick, MD 21702; and {dagger} Laboratory of Molecular Immunoregulation, Center for Cancer Research, National Cancer Institute-Frederick, Frederick, MD 21702


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Compelling evidence has now demonstrated that IL-17-producing CD4 cells (Th17) are a major contributor to autoimmune pathogenesis, whereas CD4+CD25+ T regulatory cells (Treg) play a major role in suppression of autoimmunity. Differentiation of proinflammatory Th17 and immunosuppressive Treg from naive CD4 cells is reciprocally related and contingent upon the cytokine environment. We and others have reported that in vivo administration of pertussis toxin (PTx) reduces the number and function of mouse Treg. In this study, we have shown that supernatants from PTx-treated mouse splenic cells, which contained IL-6 and other proinflammatory cytokines, but not PTx itself, overcame the inhibition of proliferation seen in cocultures of Treg and CD4+CD25– T effector cells. This stimulatory effect could be mimicked by individual inflammatory cytokines such as IL-1beta, IL-6, and TNF-{alpha}. The combination of these cytokines synergistically stimulated the proliferation of CD4+CD25– T effector cells despite the presence of Treg with a concomitant reduction in the percentage of FoxP3+ cells and generation of IL-17-expressing cells. PTx generated Th17 cells, while inhibiting the differentiation of FoxP+ cells, from naive CD4 cells when cocultured with bone marrow-derived dendritic cells from wild-type mice, but not from IL-6–/– mice. In vivo treatment with PTx induced IL-17-secreting cells in wild-type mice, but not in IL-6–/– mice. Thus, in addition to inhibiting the development of Treg, the immunoadjuvant activity of PTx can be attributable to the generation of IL-6-dependent IL-17-producing CD4 cells.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Microbial infection has been proposed to initiate clinical manifestations of autoimmune disease in genetically predisposed individuals (1). A clear-cut example of microbial environment influencing autoimmunity is the observation that TCR-transgenic mice specifically reactive to myelin basic protein did not develop experimental autoimmune encephalomyelitis (EAE)3 when housed in a sterile facility. However, such mice developed EAE when housed in a conventional animal facility, or if they were administered pertussis toxin (PTx), which apparently can act as a surrogate for the environmental microbial effects (2, 3). PTx is a well-known microbial component with immunoadjuvant effects and the capacity to enhance the severity of EAE in permissive strains, and renders resistant strains susceptible to disease induction (4, 5). In addition to inducing CNS autoimmunity, PTx has been used widely to induce autoimmune diseases in other animal models, such as orchitis (6), uveitis (7), and inflammatory myopathy (8).

PTx is a major virulence factor of Bordetella pertussis, the agent that causes human whooping cough. PTx belongs to the A-B structure class of bacterial toxins (9). Its B subunit binds to a receptor on the cell surface, and the enzymatically active A subunit disrupts intracellular signaling by irreversible ADP ribosylation of the Gi subclass of G protein (10). The mechanism by which PTx enhances autoimmunity appears rather complex and has not been completely understood. One prevailing proposal is that PTx breaks down the blood-brain barrier and thereby provides the primed T cells access to the target organ (11). However, this interpretation has recently come under scrutiny (12) due to the observation that PTx actually increased the expression of adhesion molecules, thereby initiating leukocyte infiltration into the brain (13). Accumulating evidence indicates that PTx induces the maturation of dendritic cells, which results in the expansion of T effector cells (14) and the differentiation of both Th1 and Th2 cells (12, 15). Activation of intracellular TLR4 signaling has also been implicated in PTx-mediated adjuvant activity (13, 16). Recently, we and others reported that in vivo treatment of PTx reduced the number of mouse FoxP3+ CD4+CD25+ T regulatory cells (Treg) (17, 18) and impaired the immunosuppressive functions of Treg (17).

Recent compelling evidence demonstrated that IL-17-producing T lymphocytes comprise a distinct lineage of proinflammatory Th cells, termed Th17 cells, that are major contributors to autoimmune disease (19). In contrast, Treg actively restrain the inflammatory response, suppress development of autoimmune diseases, and dampen a wide spectrum of immune responses (20, 21). Intriguingly, pathogenic Th17 and immunosuppressive Treg from naive CD4 cells are reciprocally induced, contingent upon the presence of either IL-6 or IL-2, respectively, in the presence of TGF-beta (22, 23, 24). Based on evidence that PTx has the capacity to induce proinflammatory cytokines (25), while inhibiting IL-2 mRNA transcription induction by proinflammatory cytokines (26), we hypothesized that PTx may also promote the differentiation of Th17 cells, while concommitantly inhibiting Treg (17, 18).

In this study, we show that PTx-cultured supernatant (PTx-CS) that contained IL-6 and other proinflammatory cytokines, but not PTx itself, restored the proliferative response of cocultures containing CD4+CD25– T effector cells (Teff) and Treg. Remarkably, the combination of IL-1beta, IL-6, and TNF synergistically increased lymphocyte proliferation up to 400-fold in the cocultures and allowed Teff to escape from Treg-mediated inhibition, resulting in the generation of IL-17-producing cells, while reducing the proportion of FoxP3+ cells. Treatment with PTx both in vitro and in vivo promoted the generation of IL-17-producing CD4 cells in a TGF-beta- and IL-6-dependent manner and suppressed the development of FoxP3+ CD4 cells. Our observation thus provides the first evidence that the immunoadjuvant activity of PTx may be based in part on the facilitation of IL-17 production. This property of PTx may also reflect a novel mechanism by which environmental infectious agents promote autoimmune diseases.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Mice and reagents

Female wild-type (wt) C57BL/6 (Ly5.1 and Ly5.2) and BALB/c mice, 8–12 wk old, were provided by the Animal Production Area of the National Cancer Institute. The National Cancer Institute is accredited by the American Association for the Accreditation of Laboratory Animal Care International and follows the Public Health Service Policy for the Care and Use of Laboratory Animals. Animal care was provided in accordance with the procedures outlined in the Guide for Care and Use of Laboratory Animals (National Research Council, Washington, D.C.). IL-6 knockout mice were purchased from The Jackson Laboratory. Abs purchased from BD Pharmingen consisted of FITC anti-CD3 (145-2C11), FITC anti-CD4 (GK1.5), allophycocyanin anti-CD4 (L3T4), PE anti-CD25 (PC61), allophycocyanin anti-CD25 (PC61), PE anti-IL-4 (11B11), PE anti-IL-17 (TC11-18H10), PE anti-IFN-{gamma} (XMG1.2), purified anti-CD3 (145-2C11), purified anti-CD16/CD32 (2.4G2), and anti-CD28 (35.71). PE anti-mouse/rat Foxp3 staining set (FJK-16s) was purchased from eBioscience. Recombinant mouse cytokines (TNF, IL-1beta, and IL-6) were purchased from PeproTech. PTx was purchased from List Biological Laboratories. Human rTGF-beta1 and anti-TGF-beta (1, 2, 3) Ab (1D11) were from R&D Systems.

Purification of cells

Naive CD4+ cells were isolated with mouse naive T cells CD4+/CD62L+/CD44low column kit (R&D Systems). CD4+ cells were purified with mouse CD4 (L3T4) microbeads and LS column (Miltenyi Biotec). CD4+CD25– and CD4+CD25+ cells were purified from lymph node (LN; inguinal, axillary, and mesenteric regions) and splenic cells using DakoCytomation MoFlo cytometer, yielding a purity of ~98% for both subsets. T-depleted spleen cells were used as APCs and were prepared by depletion of CD90+ cells with anti-mouse CD90 MicroBead and LD column (Miltenyi Biotec). APCs were irradiated with 3000 rad.

Generation of bone marrow-derived dendritic cells (BMDC)

Bone marrow cells were prepared from mouse femurs and tibia by flushing with culture medium. The bone marrow cells were cultured with GM-CSF (20 ng/nl), and nonadherent granulocytes were removed, as previously described, by Kubo et al. (27). BMDC were used at day 6~8.

Preparation of PTx-CS

Erythrocyte-lysed total splenic cells from wt BALB/c mice were treated with 0.1~10 µg/ml PTx for 48 h. Supernatant was harvested and stored at –70°C for future use. The cytokines contained in the PTx-CS were identified using a SearchLight Mouse Cytokine Array (Pierce Biotechnology).

In vitro cell culture and proliferation assay

For in vitro assays of inhibition of proliferation by Treg, CD4+CD25– T cells (5 x 104 cells/well) were seeded in a U-bottom 96-well plate in the medium (RPMI 1640 with 10% FBS (HyClone) containing 2 mM glutamine, 100 IU/ml penicillin, 100 µg/ml streptomycin, 10 mM HEPES, 1 mM sodium pyruvate, and 50 µM 2-ME) with 2 x 105 cells/well APCs plus 0.5 µg/ml soluble anti-CD3 Ab. CD4+CD25+ T cells were added to the wells at desired ratio to CD4+CD25– cells. Cells were pulsed with 1 µCi of [3H]thymidine (Amersham Biosciences) per well for the last 6 h of culture period. In some experiments, the medium was supplemented with PTx-CS, PTx, IFN-{gamma}, IL-1beta, IL-6, or TNF-{alpha}, or their combinations.

For CD4 cell activation, purified CD4 cells or naive CD4 cells (2.5 x 105 cells/well) were cultured with BMDC (1 x 105 cells/well) in a 24-well plate, stimulated with soluble anti-CD3 (0.5 µg/ml), in the absence or presence of PTx, for 3 days. In some experiments, TGF-beta (2 ng/ml) or anti-TGF-beta (1, 2, 3) Ab (10 µg/ml) or IL-6 (20 ng/ml) was added to the cells. In some experiments, naive CD4 cells were stimulated with plate-bound anti-CD3 (5 µg/ml) and soluble anti-CD28 (2 µg/ml) for 3 days.

In vivo treatment with PTx

The wt BALB/c, C57BL/6, or IL-6–/– mice used to evaluate the effect of PTx were injected (i.p.) with 400 ng/mouse (in 0.2 ml of PBS) per day for 2 consecutive days. One week after treatment, the mice were sacrificed, lymphoid organs were removed aseptically, and a single cell suspension was prepared for the assays.

Flow cytometry

After blocking with anti-CD16/CD32 Ab, cells were incubated with appropriately diluted Abs. For CFSE-labeling assay, cells were labeled with 2 µM CFSE for 8 min at room temperature. For intracellular cytokine staining, the cells were stimulated with PMA (20 ng/ml; Sigma-Aldrich) and ionomycin (1 µM; Sigma-Aldrich) for 5 h in the presence of GolgiPlug (BD Pharmingen). The cells were then fixed and permeabilized with Cytofix/Cytoperm (BD Pharmingen) and stained with relevant Abs. Samples were acquired on a FACSort (BD Biosciences), and data analysis was conducted using CellQuest software (BD Biosciences).

Statistical analysis

Data were analyzed by two-tailed Student’s t test using GraphPad Prism 4.0 (GraphPad).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
PTx-CS overcomes suppressed proliferation in cocultures of Teff and Treg

We previously reported that in vivo treatment with PTx reduced the number and immunosuppressive activity of mouse Treg (17). However, treatment of Treg with PTx in vitro did not reduce FoxP3 expression and their immunosuppressive activity (17). This led us to hypothesize that PTx-elicited soluble factor(s) may be responsible for the in vivo effect of PTx. To test this idea, we generated PTx-CS by stimulating total splenocytes with various concentrations of PTx (0.1~10 µg/ml) for 48 h and then added the PTx-CS to cocultures of Teff and Treg. As shown in Fig. 1A, Treg potently suppressed the proliferation of Teff, and this inhibition could be reversed by addition of PTx-CS, in a dose-dependent manner. Contaminating PTx was not responsible for this effect because addition of PTx to the cells had only a minimal effect (Fig. 1B). Thus, soluble factor(s) contained in the PTx-CS, but not PTx itself, was responsible for the enhancement of proliferation of cocultures.


Figure 1
View larger version (15K):
[in this window]
[in a new window]

  		FIGURE 1. Effect of PTx culture supernatant on proliferation of cocultures of Teff and Treg. A, PTx-CS was prepared by stimulating total splenocytes with indicated concentrations of PTx (0.1, 1, and 10 µg/ml) for 48 h. FACS-sorted CD4+CD25– cells (5 x 104 cells/well), cultured alone or cocultured with CD4+CD25+ cells (2.5 x 104 cells/well), were stimulated with APC and anti-CD3, in the presence of 50 µl of PTx-CS. The numbers under the column of PTx-CS are concentrations of PTx used to generate culture supernatant. B, In another set of experiments, PTx (1 µg/ml) or PTx-CS (stimulated with 1 µg/ml PTx) was added to cocultures of Teff and Treg (2:1). After 72-h incubation, cell proliferation was determined by [3H]thymidine incorporation assay. C, PTx stimulated production of proinflammatory cytokines and IFN-{gamma} from splenocytes. Total splenocytes were cultured in 96-well plate (106 cells/well) with medium alone or with 0.1~10 µg/ml PTx. After 48-h incubation, the supernatant was harvested, and IL-1beta, IL-6, and TNF levels were determined by multiplex mouse cytokine measurement. Data shown are representatives of three separate experiments with similar results. Error bars indicate SE derived from triplicate wells.

 
It was reported previously that proinflammatory cytokines had the capacity to abrogate inhibition of proliferation in cocultures of Treg and Teff (28, 29); we therefore identified the proinflammatory cytokines contained in PTx-CS. Consistent with previous reports (25, 30), we found that unfractionated mouse splenocytes treated with PTx produced proinflammatory cytokines, including IL-6, TNF-{alpha}, IL-1beta, as well as IFN-{gamma} in a dose-dependent manner. IL-6 appeared to be the major proinflammatory cytokine produced by PTx-treated splenocytes, because its concentration was much higher than that of TNF and IL-1beta (Fig. 1C).

Inflammatory cytokines synergize to overcome the inhibition of proliferation by Treg

Next, we examined the effect of proinflammatory cytokines on the lymphoproliferative response in cocultures of Teff and Treg. Consistent with earlier reports, exogenous IL-1beta (29) and IL-6 (28) enhanced proliferation in cocultures. Furthermore, TNF also shared this property with IL-1beta and IL-6. In contrast, IFN-{gamma} did not affect the proliferative response in cocultures. The combination of IL-1beta, IL-6, and TNF cell dramatically synergized in reversing the inhibition of proliferation in the cocultures with up to 400-fold increase in proliferation over the effect of medium alone (p < 0.0001; Fig. 2, A and B). The combination of any two inflammatory cytokines merely had an additive effect, or in the case of IL-1beta plus IL-6 a modest synergistic effect (Fig. 2, A and B). Thus, the participation of each of the three inflammatory cytokines was indispensable to yield the dramatic synergistic proliferative response in the cocultures.


Figure 2
View larger version (13K):
[in this window]
[in a new window]

  		FIGURE 2. Synergistic effect of proinflammatory cytokines on proliferation of cocultures of Teff and Treg. CD4+CD25– cells (5 x 104 cells/well), cultured alone or cocultured with CD4+CD25+ cells (2.5 x 104 cells/well), were stimulated with APC and anti-CD3, in the presence of 10 ng/ml IFN-{gamma} alone or IL-1beta, IL-6, or TNF alone, or in different combinations. After 72-h incubation, proliferation was determined by [3H]thymidine incorporation assay. A, Shows representative results from at least eight separate experiments; B, shows summary of eight separate experiments as percentage of maximal proliferation (CD4+CD25– T cells alone, %). Comparison of effect on cocultures of Teff and Treg with or without cytokine; ***, p < 0.001; ****, p < 0.0001. The dashed line indicates 100% proliferation of CD4+CD25– T cells alone. Error bars indicate SE derived from triplicate wells (A) or eight separate experiments (B).

 
To identify the subset of CD4 cells in the cocultures responsible for the proliferative response to the three cytokines, we added 0.5~10 ng/ml of each cytokine to Teff, Treg, or their cocultures, respectively, together with APC and anti-CD3. As shown in Fig. 3A, the combination of the three cytokines promoted maximal proliferation of Teff in a dose-dependent manner (p < 0.01). Consistent with previous observation, Treg were hyporesponsive to stimulation with APC and anti-CD3; however, the anergic status of Treg was overcome by the addition of the three cytokines in a dose-dependent manner (p < 0.05~0.01). Although the inhibition of proliferation in the cocultures was reversed by addition of the three cytokines (p < 0.05~0.01), the resultant proliferation in the cocultures was still less than that of cytokine-stimulated CD4+CD25– T cells at 1 ng/ml each (p < 0.001) and at 10 ng/ml each (p > 0.05), indicative of some residual inhibition by Treg. To further clarify this, we used CFSE-labeling assay to determine the proliferation of subsets of CD4 cells in culture with APC and anti-CD3. As shown in Fig. 3B, addition of the three cytokines increased proliferation of cultured CD4+CD25– cells from 65.3 to 88.3% and reversed the anergic status of Treg from 0.6 to 43.8%. Addition of the three cytokines to the cocultures resulted in a robust proliferation of 81.7% of Teff, which was even higher than the 65.3% proliferating Teff cultured in the medium alone despite the presence of Treg. In the presence of the three cytokines, Treg proliferated better in cocultures with Teff (65.8%), presumably based on the stimulation by the IL-2 produced by the cocultured Teff. Our findings are consistent with a previous observation that proinflammatory cytokines (IL-6 and IL-1) cooperated in reversing Treg anergy and potentiated their responsiveness to IL-2 (27).


Figure 3
View larger version (11K):
[in this window]
[in a new window]

  		FIGURE 3. Effect of combinations of IL-1beta, IL-6, and TNF in reversing the inhibition of proliferation of Teff by Treg and in generating IL-17-producing cells in cocultures. A, CD4+CD25– cells (5 x 104 cells/well) or CD4+CD25+ cells (5 x 104 cells/well) were cultured alone or cocultured with APC and anti-CD3, in the presence of combination of IL-1beta, IL-6, and TNF (0.5~10 ng/ml). After 72-h incubation, proliferation was determined by [3H]thymidine incorporation assay. Comparison of effects of cytokines with medium-only cultures (CD25–, CD25+, and CD25–/CD25+, respectively; *, p < 0.05; **, p < 0.01). B, CFSE-labeled Ly5.1 CD4+CD25– cells (5 x 104 cells/well), or CFSE-labeled Ly5.2 CD4+CD25+ cells (5 x 104 cells/well) were cultured alone or cocultured with APC and anti-CD3 in the presence of IL-1beta, IL-6, and TNF (10 ng/ml each). After incubation for 72 h, proliferation was analyzed by gating on CD4+CD45.2+ cells to detect CD4+CD25– cells or by gating on CD4+CD45.1+ cells to detect CD4+CD25+ cells. CFSE-labeled cells were marked with *. The percentage of CFSE-diluted cells was shown on the histogram. C, CD4+CD25– cells (5 x 104 cells/well) were cultured with CD4+CD25+ cells at a ratio of 2:1, stimulated with APC and anti-CD3, with or without IL-1beta, IL-6, and TNF (10 ng/ml, each). Seventy-two hours later, aliquot of cells was harvested, and intracellular expression of FoxP3 was analyzed by FACS (gated on CD3+CD4+ population, b). The rest of cells were restimulated with PMA and ionomycin for 5 h. Cytoplasmic expression of IL-17 was determined by FACS (gated on CD3+CD4+ population, a). Numbers in quadrants represent the frequency of cells in each. Data shown are representative of at least three separate experiments with similar results.

 
It was reported recently that IL-6 in concert with TGF-beta (or its Treg source) induced naive CD4 cells to differentiate into Th17 cells (22, 23, 24). This ability of IL-6 could be synergistically enhanced by IL-1beta and TNF (24). We therefore examined cocultures stimulated with the three cytokines and found that 11.4% of CD4 cells in the cocultures expressed IL-17 (Fig. 3Ca). In contrast, the proportion of FoxP+ cells in the presence of IL-1beta, IL-6, and TNF was reduced to 18.7%, from the 29.6% in medium culture alone (Fig. 3Cb). This presumably resulted from the overgrowth of Teff in the cocultures.

PTx treatment promotes the generation of IL-17-producing CD4 cells in vitro

Our foregoing experiment suggested that PTx may facilitate the generation of IL-17-producing CD4 cells by inducing proinflammatory cytokines. To examine this hypothesis in vitro, purified CD4 cells were cultured with BMDC in the presence of anti-CD3, with or without PTx. As shown in Fig. 4A, after treatment with PTx for 3 days, a substantial proportion (8.9%) of these CD4 cells became IL-17-producing cells. PTx-induced generation of IL-17-producing cells was markedly inhibited by anti-TGF-beta Ab. In contrast, only 0.8% of CD4 cells expressed IL-17 in the absence of PTx. Concomitantly, the proportion of FoxP3+ cells was reduced by ~50% by PTx treatment (Fig. 4B, p < 0.05), probably due to the loss of Treg, which has been shown to be more sensitive than Teff to PTx-induced cell death in vitro (18).


Figure 4
View larger version (23K):
[in this window]
[in a new window]

  		FIGURE 4. Effect of PTx on FoxP3+ cells and development of IL-17-producing cells in cultured CD4 cells. MACS-purified CD4 cells from BALB/c mice and BALB/c mouse-derived BMDC were stimulated with anti-CD3 Ab (0.5 µg/ml), in the absence or presence of PTx (5 µg/ml) with or without anti-TGF-beta Ab (10 µg/ml). After 3 days, aliquot of cells was harvested, and intracellular expression of FoxP3 was analyzed by FACS (gated on CD3+CD4+ population, B). The rest of cells were restimulated with PMA and ionomycin. Intracellular expression of IL-17 was analyzed by FACS (gated on CD3+CD4+ population, A). Numbers in quadrants represent the frequency of cells in each. The results shown are representatives of three separate experiments with similar results.

 
It has been reported that naive CD4 cells stimulated with TGF-beta and IL-6 differentiated into Th17 cells (22, 23, 24). We therefore determined whether PTx could induce naive CD4 cells to produce IL-17. When naive CD4 cells were cocultured with BMDC from wt mice, TGF-beta was able to induce the generation of FoxP3+ cells (9.3%), and this was reduced to 6.4% when PTx was added (Fig. 5Aa). In contrast with unfractionated CD4 cells, naive CD4 cells treated with PTx alone only yielded 1.2% of Th17 cells. In combination with TGF-beta, PTx was able to induce 6.6% of naive CD4 cells to produce IL-17 (Fig. 5Ab). Presumably, exogenous TGF-beta promoted differentiation of Th17 cells from naive CD4 cells and acted as a surrogate for TGF-beta-expressing Treg present in unfractionated CD4 population.


Figure 5
View larger version (28K):
[in this window]
[in a new window]

  		FIGURE 5. Effect of PTx on the differentiation of FoxP3+ cells and IL-17-producing cells from naive CD4 cells. The wt C57BL/6 naive CD4 cells were cultured with BMDC derived from either wt C57BL/6 mice (A) or IL-6 knockout mice (B) with soluble anti-CD3 Ab (0.5 µg/ml), in the presence of medium alone, PTx (1 µg/ml) alone, TGF-beta (2 ng/ml) alone, or PTx plus TGF-beta. a, After 3 days, aliquot of cells was harvested, and intracellular expression of FoxP3 was analyzed by FACS (gated on CD3+CD4+ population). b, The rest of cells were restimulated with PMA and ionomycin. Intracellular expression of IL-17 was determined by FACS (gated on CD3+CD4+ population). Numbers in quadrants represent the frequency of cells in each. The data were representatives of three separate experiments with similar results.

 
PTx, rather than suppressing, actually enhanced the TGF-beta-mediated generation of FoxP3+ cells from naive CD4 cells when they were cultured with BMDC derived from IL-6–/– mice (from 9.9 to 16.6%; Fig. 5Ba). Furthermore, the combination of TGF-beta and PTx failed to induce Th17 cells when IL-6-deficient BMDC was used (Fig. 5Bb). Thus, in the absence of IL-6 signaling, naive CD4 cells developed into Treg, rather than producing Th17 cells, in response to PTx.

PTx treatment promotes the generation of IL-17-producing CD4 cells in vivo

To verify our in vitro observation in an in vivo setting, PTx was injected into wt BALB/c mice using the same regimen we used to induce EAE (31). One week after PTx treatment, LN cells and splenic cells were restimulated in vitro with PMA and ionomycin. An appreciable fraction of LN and splenic cells from PTx-treated mice expressed IL-17 (7.8 and 6.5% in the LN and splenic cells, respectively). By comparison, only 0.9 and 1.2% in the LN and splenic cells from control mice (injected with PBS) expressed IL-17 (Fig. 6A). Presumably, PTx may promote the generation of Th17 cells to a greater degree when coadministrated with autoantigen to induce experimental autoimmune disease. The generation of Th1 (IFN-{gamma}-producing) cells and Th2 (IL-4-producing) cells from BALB/c mice was also examined. As shown in Fig. 6, B and C, the proportion of IFN-{gamma}-producing splenic CD4 cells was markedly reduced in PTx-treated mice (6.3%), as compared with CD4 splenic cells from control mice (9.9%, p < 0.01). In contrast, the proportion of IL-4-producing cells was not significantly changed by PTx treatment (p > 0.05). Again, the proportion of FoxP3+ cells in CD3+CD4+ subpopulation was reduced by ~50% (Fig. 6D). The capacity of PTx to induce Th17 cells in vivo was IL-6 dependent, because injection of PTx resulted in only 1.2% of IL-17-producing cells in IL-6–/– mouse LN cells and 6% in IL-6+/+ wt C57BL/6 mouse LN cells (Fig. 6E). Thus, in vivo treatment with PTx not only reduced the number of Treg, but also selectively enhanced the generation of IL-17-producing cells in an IL-6-dependent manner.


Figure 6
View larger version (20K):
[in this window]
[in a new window]

  		FIGURE 6. Effect of in vivo administration of PTx on development of IL-17-producing cells. A–D, wt BALB/c mice were treated with PTx (400 ng/mouse, i.p.) for 2 days. One week after the last treatment, LN and spleen cells were harvested and restimulated in vitro with PMA and ionomycin. The intracellular expression of IL-17 on LN cells (Aa) and splenic cells (Ab), IFN-{gamma} (B), and IL-4 (C) on splenic cells was analyzed by FACS (gated on CD3+CD4+ population). D, The percentage of FoxP3+ cells was analyzed by FACS (gated on CD3+CD4+ splenic cells, freshly isolated). E, wt C57BL/6 mice or IL-6 knockout mice were injected with PTx, as in A. One week after treatment, the LN cells were restimulated in vitro with PMA and ionomycin. The intracellular expression of IL-17 by splenic cells was analyzed by FACS (gated on CD3+CD4+ population). Numbers in quadrants represent the frequency of cells in each. The data were representatives of three separate experiments with similar results.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
In this study, we examined the effect of PTx on the generation of IL-17-producing CD4 cells in both in vitro as well as in vivo settings. Our findings support the conclusion that PTx, through proinflammatory cytokine pathway, facilitates the generation of IL-17-producing cells, which may contribute to its immunological adjuvant activity. This is compatible with the observation that administration of PTx stimulates the development of considerably more pathogenic Th17 cells in mice of immune-mediated ocular inflammation (7) than other TLR ligands, such as LPS, polyinosinic-polycytidylic acid, and, particularly, CpG oligodeoxynucleotide (G. Shi, unpublished observation). Furthermore, during the preparation of this manuscript, it was reported that immunization with whole cell pertussis vaccination in mice results in the generation of Th17 cells (32). This is probably due to Th17-promoting effect of PTx, as shown in our study.

Proinflammatory cytokines have been shown to possess immunological adjuvant-like effects. For example, proinflammatory cytokines have been reported to improve both the expansion and survival of effector CD4 T cells, presumably by providing a third signal in addition to the Ag-specific signal delivered by MHC-peptide complex and costimulatory molecules (33, 34, 35). Combination of IL-1beta, IL-6, and TNF, or use of an adjuvant that induces these cytokines was reportedly able to overcome age-related defects in CD4 T cell response in vitro and in vivo (36). According to our observation, this combination of proinflammatory cytokines resulted in a robust proliferation of Teff despite the presence of Treg. Our finding provides a novel interpretation for the adjuvant-like action of proinflammatory cytokines based on the observation that this combination of proinflammatory cytokines actually also suppresses the proportion and function of Treg. Although the combination of proinflammatory cytokines may induce autoimmune responses, this combination may warrant further study as an immunotherapy in patients failing to respond to conventional treatment to cancer and AIDS.

It is now well established that Th17 plays an important role in the pathogenesis of EAE (37). PTx is indispensable to generate EAE in a genetically resistant mouse strain (38). It is therefore not surprising that PTx actually facilitates the generation of IL-17 production in response to a proinflammatory cytokine pathway. IL-6 is a crucial cytokine in the generation of Th17 cells (22, 23, 24), and IL-1 is able to enhance IL-23-mediated production of IL-17 (39) as well as IL-6-mediated differentiation of Th17 cells (24). IL-6 knockout mice are completely resistant to EAE induction despite the administration of PTx (22, 40). Mice deficient in IL-1 signals (IL-1 knockout or IL-1RI knockout) are also resistant to EAE induction in response to the adjuvant effects of PTx, whereas IL-1R antagonist knockout mice can develop EAE even without PTx administration (39, 41, 42). Thus, it appears that PTx uses the Th17 pathway as well as IL-1 and IL-6 to trigger autoimmune EAE pathogenesis.

Previous reports showed that PTx promoted Th1 differentiation (12, 15), and IFN-{gamma} (as well as IL-4) was reported to inhibit the differentiation of Th17 cells (22, 23, 24). Indeed, we also observed that in vitro treatment with PTx resulted in the production of IFN-{gamma} from splenic cells. However, because PTx is able to promote generation of Th17 cells in vitro and in vivo, the proinflammatory cytokines elicited by PTx appear to prevail over any coproduced Th1 (or Th2) cytokines. Furthermore, following in vitro restimulation with PMA and ionomycin, splenic cells isolated from PTx-treated BALB/c mice actually contained fewer IFN-{gamma}-producing CD4+ cells than cells isolated from PBS-treated control mice (Fig. 6B). This discrepancy may be attributable to the reported dual actions of PTx (43) and the potential suppressive effects of IL-17 on the differentiation of Th1 cells.

In our experimental studies, PTx was able to induce IL-17-producing cells from unfractionated CD4 cells that were cocultured with BMDC. However, neutralization of TGF-beta partially blocked the generation of IL-17-producing cells by PTx (Fig. 4). These data suggest that TGF-beta plays an important role in generation of IL-17-producing cells in response to PTx, and that naturally occurring Treg might be a major source of TGF-beta. This notion is supported by the observation that PTx had very limited effect on the generation of IL-17-producing cells from naive CD4 cells, which were cocultured with wt BMDC. In contrast, exogenous TGF-beta was able to restore the capacity of PTx to induce a substantial population of IL-17-producing cells (Fig. 5Ab). Therefore, although reducing the number of Treg, PTx may need some Treg to provide TGF-beta to initiate the generation of Th17 cells. Surprisingly, PTx promoted TGF-beta-mediated differentiation of FoxP3+ Treg from naive CD4 cells that were cocultured with BMDC derived from IL-6 knockout mice (Fig. 5Ba). Presumably, BMDC from IL-6 knockout mice can be activated by PTx to produce cytokines such as IL-1 and TNF and consequently activate cocultured CD4 cells to produce IL-2. It is known that activated dendritic cells themselves (for review, see Ref. 44), cytokines such as IL-2 (for review, see Ref. 45), and IL-1 (27) are capable of expanding Treg. Furthermore, we previously observed that TNF also could selectively and directly expand Treg by interacting with TNFR2, which is preferentially expressed by Treg, in the absence of IL-6 (our unpublished observation). Therefore, PTx has the capacity to elicit an IL-6-independent Treg response in cocultures of naive CD4 cells and BMDC, whereas PTx favors induction of the Th17 pathway in the presence of IL-6.

Taken together, we have revealed the capacity of PTx to promote generation of IL-17-producing CD4 cells through a proinflammatory cytokine pathway. This action of PTx may certainly contribute to the immunological adjuvant effect of PTx. PTx is a major virulence factor of B. pertussis, and infection by this pathogen was reported to be capable of being an initiation or developmental factor of autoimmune disease (46, 47). Thus, our findings may represent a novel mechanism by which this environmental microbial toxin can promote autoimmunity.


   Acknowledgments
 
We cordially appreciate Drs. Igal Gery and Guangpu Shi (Laboratory of Immunology, National Eye Institute, National Institutes of Health) for their helpful discussion.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract N01-CO-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. government. This research was supported (in part) by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research. Back

2 Address correspondence and reprint requests to Dr. Xin Chen, Basic Research Program, SAIC-Frederick, Inc., Laboratory of Molecular Immunoregulation, National Cancer Institute-Frederick, P.O. Box B, Building 560, Room 31-19, Frederick, MD 21702-1201. E-mail address: chenxin{at}mail.nih.gov Back

3 Abbreviations used in this paper: EAE, experimental autoimmune encephalomyelitis; BMDC, bone marrow-derived dendritic cell; LN, lymph node; PTx, pertussis toxin; PTx-CS, PTx-cultured supernatant; Teff, CD4+CD25– T effector cell; Treg, CD4+CD25+ T regulatory cell; wt, wild type. Back

Received for publication December 8, 2006. Accepted for publication February 27, 2007.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Christen, U., M. G. von Herrath. 2005. Infections and autoimmunity: good or bad?. J. Immunol. 174: 7481-7486. [Abstract/Free Full Text]
  2. Goverman, J., A. Woods, L. Larson, L. P. Weiner, L. Hood, D. M. Zaller. 1993. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 72: 551-560. [Medline]
  3. Brabb, T., A. W. Goldrath, P. von Dassow, A. Paez, H. D. Liggitt, J. Goverman. 1997. Triggers of autoimmune disease in a murine TCR-transgenic model for multiple sclerosis. J. Immunol. 159: 497-507. [Abstract]
  4. Munoz, J. J., C. C. Bernard, I. R. Mackay. 1984. Elicitation of experimental allergic encephalomyelitis (EAE) in mice with the aid of pertussigen. Cell. Immunol. 83: 92-100. [Medline]
  5. Linthicum, D. S.. 1982. Development of acute autoimmune encephalomyelitis in mice: factors regulating the effector phase of the disease. Immunobiology 162: 211-220. [Medline]
  6. Kohno, S., J. A. Munoz, T. M. Williams, C. Teuscher, C. C. Bernard, K. S. Tung. 1983. Immunopathology of murine experimental allergic orchitis. J. Immunol. 130: 2675-2682. [Abstract]
  7. Fujimoto, C., C. R. Yu, G. Shi, B. P. Vistica, E. F. Wawrousek, D. M. Klinman, C. C. Chan, C. E. Egwuagu, I. Gery. 2006. Pertussis toxin is superior to TLR ligands in enhancing pathogenic autoimmunity, targeted at a neo-self antigen, by triggering robust expansion of Th1 cells and their cytokine production. J. Immunol. 177: 6896-6903. [Abstract/Free Full Text]
  8. Hart, M. N., D. S. Linthicum, M. M. Waldschmidt, S. K. Tassell, R. L. Schelper, R. A. Robinson. 1987. Experimental autoimmune inflammatory myopathy. J. Neuropathol. Exp. Neurol. 46: 511-521. [Medline]
  9. Burnette, W. N.. 1997. Bacterial ADP-ribosylating toxins: form, function, and recombinant vaccine development. Behring Inst. Mitt. 98: 434-441. [Medline]
  10. Falnes, P. O., K. Sandvig. 2000. Penetration of protein toxins into cells. Curr. Opin. Cell Biol. 12: 407-413. [Medline]
  11. Linthicum, D. S., J. J. Munoz, A. Blaskett. 1982. Acute experimental autoimmune encephalomyelitis in mice. I. Adjuvant action of Bordetella pertussis is due to vasoactive amine sensitization and increased vascular permeability of the central nervous system. Cell. Immunol. 73: 299-310. [Medline]
  12. Hofstetter, H. H., C. L. Shive, T. G. Forsthuber. 2002. Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund’s adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J. Immunol. 169: 117-125. [Abstract/Free Full Text]
  13. Kerfoot, S. M., E. M. Long, M. J. Hickey, G. Andonegui, B. M. Lapointe, R. C. Zanardo, C. Bonder, W. G. James, S. M. Robbins, P. Kubes. 2004. TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J. Immunol. 173: 7070-7077. [Abstract/Free Full Text]
  14. Wakatsuki, A., P. Borrow, K. Rigley, P. C. Beverley. 2003. Cell-surface bound pertussis toxin induces polyclonal T cell responses with high levels of interferon-{gamma} in the absence of interleukin-12. Eur. J. Immunol. 33: 1859-1868. [Medline]
  15. Hou, W., Y. Wu, S. Sun, M. Shi, Y. Sun, C. Yang, G. Pei, Y. Gu, C. Zhong, B. Sun. 2003. Pertussis toxin enhances Th1 responses by stimulation of dendritic cells. J. Immunol. 170: 1728-1736. [Abstract/Free Full Text]
  16. Wang, Z. Y., D. Yang, Q. Chen, C. A. Leifer, D. M. Segal, S. B. Su, R. R. Caspi, Z. O. Howard, J. J. Oppenheim. 2006. Induction of dendritic cell maturation by pertussis toxin and its B subunit differentially initiate Toll-like receptor 4-dependent signal transduction pathways. Exp. Hematol. 34: 1115-1124. [Medline]
  17. Chen, X., R. T. Winkler-Pickett, N. H. Carbonetti, J. R. Ortaldo, J. J. Oppenheim, O. M. Howard. 2006. Pertussis toxin as an adjuvant suppresses the number and function of CD4+CD25+ T regulatory cells. Eur. J. Immunol. 36: 671-680. [Medline]
  18. Cassan, C., E. Piaggio, J. P. Zappulla, L. T. Mars, N. Couturier, F. Bucciarelli, S. Desbois, J. Bauer, D. Gonzalez-Dunia, R. S. Liblau. 2006. Pertussis toxin reduces the number of splenic Foxp3+ regulatory T cells. J. Immunol. 177: 1552-1560. [Abstract/Free Full Text]
  19. Weaver, C. T., L. E. Harrington, P. R. Mangan, M. Gavrieli, K. M. Murphy. 2006. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24: 677-688. [Medline]
  20. Shevach, E. M., R. A. DiPaolo, J. Andersson, D. M. Zhao, G. L. Stephens, A. M. Thornton. 2006. The lifestyle of naturally occurring CD4+CD25+Foxp3+ regulatory T cells. Immunol. Rev. 212: 60-73. [Medline]
  21. Sakaguchi, S., M. Ono, R. Setoguchi, H. Yagi, S. Hori, Z. Fehervari, J. Shimizu, T. Takahashi, T. Nomura. 2006. Foxp3+CD25+CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212: 8-27. [Medline]
  22. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, V. K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238. [Medline]
  23. Mangan, P. R., L. E. Harrington, D. B. O’Quinn, W. S. Helms, D. C. Bullard, C. O. Elson, R. D. Hatton, S. M. Wahl, T. R. Schoeb, C. T. Weaver. 2006. Transforming growth factor-beta induces development of the TH17 lineage. Nature 441: 231-234. [Medline]
  24. Veldhoen, M., R. J. Hocking, C. J. Atkins, R. M. Locksley, B. Stockinger. 2006. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24: 179-189. [Medline]
  25. Tonon, S., S. Goriely, E. Aksoy, O. Pradier, G. Del Giudice, E. Trannoy, F. Willems, M. Goldman, D. De Wit. 2002. Bordetella pertussis toxin induces the release of inflammatory cytokines and dendritic cell activation in whole blood: impaired responses in human newborns. Eur. J. Immunol. 32: 3118-3125. [Medline]
  26. Zumbihl, R., J. Dornand, T. Fischer, S. Cabane, R. Rappuoli, M. Bouaboula, P. Casellas, B. Rouot. 1995. IL-1 stimulates a diverging signaling pathway in EL4 6.1 thymoma cells: IL-2 release, but not IL-2 receptor expression, is sensitive to pertussis toxin. J. Immunol. 155: 181-189. [Abstract]
  27. Kubo, T., R. D. Hatton, J. Oliver, X. Liu, C. O. Elson, C. T. Weaver. 2004. Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J. Immunol. 173: 7249-7258. [Abstract/Free Full Text]
  28. Pasare, C., R. Medzhitov. 2003. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033-1036. [Abstract/Free Full Text]
  29. O’Sullivan, B. J., H. E. Thomas, S. Pai, P. Santamaria, Y. Iwakura, R. J. Steptoe, T. W. Kay, R. Thomas. 2006. IL-1beta breaks tolerance through expansion of CD25+ effector T cells. J. Immunol. 176: 7278-7287. [Abstract/Free Full Text]
  30. Ausiello, C. M., G. Fedele, F. Urbani, R. Lande, B. Di Carlo, A. Cassone. 2002. Native and genetically inactivated pertussis toxins induce human dendritic cell maturation and synergize with lipopolysaccharide in promoting T helper type 1 responses. J. Infect. Dis. 186: 351-360. [Medline]
  31. Chen, X., J. J. Oppenheim, R. T. Winkler-Pickett, J. R. Ortaldo, O. M. Howard. 2006. Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3+CD4+CD25+ T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur. J. Immunol. 36: 2139-2149. [Medline]
  32. Higgins, S. C., A. G. Jarnicki, E. C. Lavelle, K. H. Mills. 2006. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J. Immunol. 177: 7980-7989. [Abstract/Free Full Text]
  33. Curtsinger, J. M., C. S. Schmidt, A. Mondino, D. C. Lins, R. M. Kedl, M. K. Jenkins, M. F. Mescher. 1999. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J. Immunol. 162: 3256-3262. [Abstract/Free Full Text]
  34. Pape, K. A., A. Khoruts, A. Mondino, M. K. Jenkins. 1997. Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J. Immunol. 159: 591-598. [Abstract]
  35. Vella, A. T., T. Mitchell, B. Groth, P. S. Linsley, J. M. Green, C. B. Thompson, J. W. Kappler, P. Marrack. 1997. CD28 engagement and proinflammatory cytokines contribute to T cell expansion and long-term survival in vivo. J. Immunol. 158: 4714-4720. [Abstract]
  36. Haynes, L., S. M. Eaton, E. M. Burns, M. Rincon, S. L. Swain. 2004. Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo. J. Immunol. 172: 5194-5199. [Abstract/Free Full Text]
  37. Komiyama, Y., S. Nakae, T. Matsuki, A. Nambu, H. Ishigame, S. Kakuta, K. Sudo, Y. Iwakura. 2006. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177: 566-573. [Abstract/Free Full Text]
  38. Munoz, J. J., I. R. Mackay. 1984. Production of experimental allergic encephalomyelitis with the aid of pertussigen in mouse strains considered genetically resistant. J. Neuroimmunol. 7: 91-96. [Medline]
  39. Sutton, C., C. Brereton, B. Keogh, K. H. Mills, E. C. Lavelle. 2006. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 203: 1685-1691. [Abstract/Free Full Text]
  40. Samoilova, E. B., J. L. Horton, B. Hilliard, T. S. Liu, Y. Chen. 1998. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J. Immunol. 161: 6480-6486. [Abstract/Free Full Text]
  41. Schiffenbauer, J., W. J. Streit, E. Butfiloski, M. LaBow, C. Edwards, III, L. L. Moldawer. 2000. The induction of EAE is only partially dependent on TNF receptor signaling but requires the IL-1 type I receptor. Clin. Immunol. 95: 117-123. [Medline]
  42. Matsuki, T., S. Nakae, K. Sudo, R. Horai, Y. Iwakura. 2006. Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis. Int. Immunol. 18: 399-407. [Abstract/Free Full Text]
  43. Vistica, B. P., C. G. McAllister, R. D. Sekura, J. N. Ihle, I. Gery. 1986. Dual effects of pertussis toxin on lymphoid cells in culture. Cell. Immunol. 101: 232-241. [Medline]
  44. Yamazaki, S., K. Inaba, K. V. Tarbell, R. M. Steinman. 2006. Dendritic cells expand antigen-specific Foxp3+CD25+CD4+ regulatory T cells including suppressors of alloreactivity. Immunol. Rev. 212: 314-329. [Medline]
  45. Malek, T. R., A. L. Bayer. 2004. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 4: 665-674. [Medline]
  46. Montgomery, S. M., A. G. Ehlin, A. Ekbom, A. J. Wakefield. 2002. Pertussis infection in childhood and subsequent type 1 diabetes mellitus. Diabet. Med. 19: 986-993. [Medline]
  47. Bachmann, S., J. Kesselring. 1998. Multiple sclerosis and infectious childhood diseases. Neuroepidemiology 17: 154-160. [Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
H. M. S. Algood, S. S. Allen, M. K. Washington, R. M. Peek Jr., G. G. Miller, and T. L. Cover
Regulation of Gastric B Cell Recruitment Is Dependent on IL-17 Receptor A Signaling in a Model of Chronic Bacterial Infection
J. Immunol., November 1, 2009; 183(9): 5837 - 5846.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y.-S. Kim, S.-W. Hong, J.-P. Choi, T.-S. Shin, H.-G. Moon, E.-J. Choi, S. G. Jeon, S.-Y. Oh, Y. S. Gho, Z. Zhu, et al.
Vascular Endothelial Growth Factor Is a Key Mediator in the Development of T Cell Priming and Its Polarization to Type 1 and Type 17 T Helper Cells in the Airways
J. Immunol., October 15, 2009; 183(8): 5113 - 5120.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Noris, P. Cassis, N. Azzollini, R. Cavinato, D. Cugini, F. Casiraghi, S. Aiello, S. Solini, L. Cassis, M. Mister, et al.
The Toll-IL-1R Member Tir8/SIGIRR Negatively Regulates Adaptive Immunity against Kidney Grafts
J. Immunol., October 1, 2009; 183(7): 4249 - 4260.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Nasso, G. Fedele, F. Spensieri, R. Palazzo, P. Costantino, R. Rappuoli, and C. M. Ausiello
Genetically Detoxified Pertussis Toxin Induces Th1/Th17 Immune Response through MAPKs and IL-10-Dependent Mechanisms
J. Immunol., August 1, 2009; 183(3): 1892 - 1899.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. M. Spach, R. Noubade, B. McElvany, W. F. Hickey, E. P. Blankenhorn, and C. Teuscher
A Single Nucleotide Polymorphism in Tyk2 Controls Susceptibility to Experimental Allergic Encephalomyelitis
J. Immunol., June 15, 2009; 182(12): 7776 - 7783.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
C. Andreasen and N. H. Carbonetti
Pertussis Toxin Inhibits Early Chemokine Production To Delay Neutrophil Recruitment in Response to Bordetella pertussis Respiratory Tract Infection in Mice
Infect. Immun., November 1, 2008; 76(11): 5139 - 5148.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
L. de Beaucoudrey, A. Puel, O. Filipe-Santos, A. Cobat, P. Ghandil, M. Chrabieh, J. Feinberg, H. von Bernuth, A. Samarina, L. Janniere, et al.
Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells
J. Exp. Med., July 7, 2008; 205(7): 1543 - 1550.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Fedele, M. Nasso, F. Spensieri, R. Palazzo, L. Frasca, M. Watanabe, and C. M. Ausiello
Lipopolysaccharides from Bordetella pertussis and Bordetella parapertussis Differently Modulate Human Dendritic Cell Functions Resulting in Divergent Prevalence of Th17-Polarized Responses
J. Immunol., July 1, 2008; 181(1): 208 - 216.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Noubade, N. Saligrama, K. Spach, R. del Rio, E. P. Blankenhorn, T. Kantidakis, G. Milligan, M. Rincon, and C. Teuscher
Autoimmune Disease-Associated Histamine Receptor H1 Alleles Exhibit Differential Protein Trafficking and Cell Surface Expression
J. Immunol., June 1, 2008; 180(11): 7471 - 7479.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
D. Noguchi, D. Wakita, M. Tajima, S. Ashino, Y. Iwakura, Y. Zhang, K. Chamoto, H. Kitamura, and T. Nishimura
Blocking of IL-6 signaling pathway prevents CD4+ T cell-mediated colitis in a Th17-independent manner
Int. Immunol., December 1, 2007; 19(12): 1431 - 1440.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, X.
Right arrow Articles by Oppenheim, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, X.
Right arrow Articles by Oppenheim, J. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS